Sailun Bio released its 2026 interim report, showing first-half net profit attributable to the parent of 35.65 million yuan, an increase of 8.1% year on year. Operating revenue was 104 million yuan, up 3.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 31.08 million yuan, up 9.0% year on year. Net operating cash flow was 8.04 million yuan, up 137.8% year on year. Second-quarter net profit attributable to the parent was 35.08 million yuan, up 20.1% year on year. The company said its business operations have not undergone major changes, remaining focused on the production, research and development, and sales of antiserum and antitoxin products. Research and development expenses rose 25.98% year on year.
Shanghai Serum Bio-Technology Co. Ltd. AFirst-half net profit up 8.1% year on year, with Q2 profit up 20.1%.
